Document is current
Any future updates will be listed below
-
Authors
Yadav, Kritika
Mohan, Meera https://orcid.org/0000-0002-6913-6526
Wagner, Charlotte https://orcid.org/0000-0003-0568-0781
Chakraborty, Rajshekhar
Sborov, Douglas
Godara, Amandeep
McClune, Brian
Schinke, Carolina https://orcid.org/0000-0002-2699-1741
Dhakal, Binod https://orcid.org/0000-0002-4377-9742
D’Souza, Anita https://orcid.org/0000-0002-1092-5643
Szabo, Aniko https://orcid.org/0000-0002-8129-0614
Mohyuddin, Ghulam Rehman https://orcid.org/0000-0001-6464-783X
- License Information
-
More Information
Article History
Received: 12 March 2025
Revised: 18 June 2025
Accepted: 7 July 2025
First Online: 16 July 2025
Competing interests
: Dr. Sborov has reported consulting or advisory roles for Sanofi, GlaxoSmithKline, Bristol Myers Squibb, Legend Biotech, Janssen, Pfizer, Bioline, AstraZeneca, Arcellx, Abbvie, and Genentech, Inc.; research funding from Pfizer; honoraria from Binaytara Foundation; and membership on the Board of Directors or advisory committees for Society of Utah Medical Oncology. Dr. Godara has reported consulting relationships with Janssen and Sanofi, and honoraria from Janssen. Dr. Chakraborty has reported consulting or advisory roles for Adaptive, Janssen, and Sanofi. Dr. D’Souza has reported consulting or advisory roles for Pfizer, Janssen Oncology, Akcea Therapeutics, Bristol Myers Squibb/Celgene, and Prothena. Dr. Mohyuddin reports research funding to institution from Janssen. Drs. Yadav, Mohan, Wagner, Schinke, Dhakal, McClune, and Szabo have no specific conflicts of interest to disclose.
: The study was approved by the Ethics Committee of each hospital (IRB-00179264) and conducted in compliance with the Declaration of Helsinki.
: Informed consent was obtained in accordance with local ethical and legal requirements.
